Get started
Author

Arnab Basu

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study
2021 · Vadim S. Koshkin, Nicholas Henderson, et al. · Cancer · 88
PDF
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study
2024 · Toni K Choueiri, Laurence Albiges, et al. · The Lancet · 81
PDF
Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients
2018 · Monica Khunger, Pradnya Dinkar Patil, et al. · PLoS ONE · 71
PDF
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
2025 · Rohan Garje, Irbaz Bin Riaz, et al. · Journal of Clinical Oncology · 66
Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer
2024 · John P. Sfakianos, Arnab Basu, et al. · European Urology Oncology · 42
Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma
2023 · Patrick L. Sweeney, Yash Suri, et al. · Cancer Drug Resistance · 37
PDF
Association of PD-L1, PD-L2, and Immune Response Markers in Matched Renal Clear Cell Carcinoma Primary and Metastatic Tissue Specimens
2018 · Arnab Basu, Jennifer Holmes Yearley, et al. · American Journal of Clinical Pathology · 29
Understanding the Uptake and Challenges of Genetic Testing Guidelines for Prostate Cancer Patients
2022 · Yash Suri, Jonathan Parham Yasmeh, et al. · Cancer Treatment and Research Communications · 28
PDF
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles
2024 · Pedro Barata, Shuchi Gulati, et al. · Journal of Clinical Investigation · 24
PDF
High sensitivity ctDNA assays in genitourinary malignancies: current evidence and future directions
2024 · Kartik R Patel, Soroush Rais-Bahrami, et al. · The Oncologist · 23
Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma
2024 · Arnab Basu, Cherry Au, et al. · JCO Precision Oncology · 18
PDF
Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer
2019 · Jeremy Chang, Jeffrey Tran, et al. · BMJ Case Reports · 17
Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study.
2024 · Tanya Jindal, Cindy Y. Jiang, et al. · Journal of Clinical Oncology · 15
Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort
2020 · Pedro Barata, Whitley Hatton, et al. · Frontiers in Oncology · 15
PDF
Longitudinal detection of circulating tumor DNA in patients with advanced renal cell carcinoma.
2023 · Arnab Basu, Revathi Kollipara, et al. · Journal of Clinical Oncology · 13
Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study
2025 · Amanda Nizam, Charles B. Nguyen, et al. · Cancer Medicine · 12
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study
2025 · Tanya Jindal, Cindy Y. Jiang, et al. · European Urology · 11
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data
2024 · Tanya Jindal, Cindy Jiang, et al. · European Urology Oncology · 11
Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer
2022 · Meredith N Freeman, Albert Jang, et al. · The Oncologist · 11
PDF
Emerging perioperative therapeutic approaches in muscle invasive bladder cancer
2022 · Goutham Patil, Arnab Basu · Therapeutic Advances in Urology · 11
Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
2023 · Tanya Jindal, Li Zhang, et al. · Journal of Clinical Oncology · 10
Neoadjuvant Therapies for Bladder Cancer in Cisplatin-ineligible Patients: What Options Do We Have?
2019 · Arnab Basu, Sarmad Sadeghi · European Urology Focus · 10
Relationship between neutrophil lymphocyte ratio (NLR) and MDSC concentration in localized and metastatic castration resistant prostate cancer (mCRPC) patients.
2018 · Arnab Basu, Kanthi Athreya Kollengode, et al. · Journal of Clinical Oncology · 8
HER2 alterations across solid tumors: implications for comprehensive testing
2025 · Ahmed Ismail, Chinmay T Jani, et al. · The Oncologist · 7
PDF
High Sensitivity Circulating Tumor-DNA Assays in Renal Cell Carcinoma–Are we there yet?
2024 · Fady Sidhom, Shefali Patel, et al. · Clinical Genitourinary Cancer · 7
Works count: 91
Citation count: 776
H-index: 14
I10-index: 22
Year
Topic
Type